Edda Spiekerkoetter

Publications

• RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension
  Rhodes, C. J., Im, H., Cao, A., Hennigs, J. K., Wang, L., & Rabinovitch, M. (2015). RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 192(3), 356-366.
• Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension.
  Spiekerkoetter, E., Sung, Y. K., Sudheendra, D., Bill, M., Aldred, M. A., & Zamanian, R. T. (2015). Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. American journal of respiratory and critical care medicine, 192(2), 254-257.
• Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling
  Nickel, N. P., Spiekerkoetter, E., Gu, M., Li, C. G., Li, H., & Rabinovitch, M. (2015). Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 191(11), 1273-1286.
• Hedgehog Signaling Restrains Bladder Cancer Progression by Eliciting Stromal Production of Urothelial Differentiation Factors Shin, K., Lim, A., Zhao, C., Sahoo, D., Pan, Y., & Beachy, P. A. (2014). Hedgehog Signaling Restrains Bladder Cancer Progression by Eliciting Stromal Production of Urothelial Differentiation Factors. CANCER CELL, 26(4), 521-533.
  
• Targeting the Wnt signaling pathways in pulmonary arterial hypertension. de Jesus Perez, V., Yuan, K., Alastalo, T.-P., Spiekerkoetter, E., & Rabinovitch, M. (2014). Targeting the Wnt signaling pathways in pulmonary arterial hypertension. Drug discovery today, 19(8), 1270-1276.
  
• Current Clinical Management of Pulmonary Arterial Hypertension Zamanian, R. T., Kudelko, K. T., Sung, Y. K., Perez, V. D. J., Liu, J., & Spiekerkoetter, E. (2014). Current Clinical Management of Pulmonary Arterial Hypertension. CIRCULATION RESEARCH, 115(1), 131-147.
  
• Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension Sawada, H., Saito, T., Nickel, N. P., Alastalo, T.-P., Glotzbach, J. P., & Rabinovitch, M. (2014). Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension. JOURNAL OF EXPERIMENTAL MEDICINE, 211(2), 263-280.
  
• FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. Spiekerkoetter, E., Tian, X., Cai, J., Hopper, R. K., Sudheendra, D., & Rabinovitch, M. (2013). FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. journal of clinical investigation, 123(8), 3600-3613.
  
• A case of recurrent pericardial constriction presenting with severe pulmonary hypertension. Brunner, N. W., Ramachandran, K., Kudelko, K. T., Sung, Y. K., Spiekerkoetter, E., & Perez, V. J. (2013). A case of recurrent pericardial constriction presenting with severe pulmonary hypertension. Pulmonary circulation, 3(2), 436-439.
  
• Loss of adenomatous poliposis coli-a3 integrin interaction promotes endothelial apoptosis in mice and humans. de Jesus Perez, V. A., Yuan, K., Orcholski, M. E., Sawada, H., Zhao, M., & Rabinovitch, M. (2012). Loss of adenomatous poliposis coli-a3 integrin interaction promotes endothelial apoptosis in mice and humans. Circulation research, 111(12), 1551-1564.
  
• Safety and Efficacy of Transition from Systemic Prostanoids to Inhaled Treprostinil in Pulmonary Arterial Hypertension Perez, V. A. J., Rosenzweig, E., Rubin, L. J., Poch, D., Bajwa, A., & Zamanian, R. T. (2012). Safety and Efficacy of Transition from Systemic Prostanoids to Inhaled Treprostinil in Pulmonary Arterial Hypertension. AMERICAN JOURNAL OF CARDIOLOGY, 110(10), 1546-1550.
  
• Neutrophil Elastase Is Produced by Pulmonary Artery Smooth Muscle Cells and Is Linked to Neointimal Lesions Kim, Y.-M., Haghighat, L., Spiekerkoetter, E., Sawada, H., Alvira, C. M., & Rabinovitch, M. (2011). Neutrophil Elastase Is Produced by Pulmonary Artery Smooth Muscle Cells and Is Linked to Neointimal Lesions. AMERICAN JOURNAL OF PATHOLOGY, 179(3), 1560-1572.
  
• BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways Perez, V. A. J., Ali, Z., Alastalo, T.-P., Ikeno, F., Sawada, H., & Rabinovitch, M. (2011). BMP promotes motility and represses growth of smooth muscle cells by activation of tandem Wnt pathways. JOURNAL OF CELL BIOLOGY, 192(1), 171-188.
  
• S100A4 and Bone Morphogenetic Protein-2 Codependently Induce Vascular Smooth Muscle Cell Migration via Phospho-Extracellular Signal-Regulated Kinase and Chloride Intracellular Channel 4 Spiekerkoetter, E., Guignabert, C., Perez, V. D. J., Alastalo, T.-P., Powers, J. M., & Rabinovitch, M. (2009). S100A4 and Bone Morphogenetic Protein-2 Codependently Induce Vascular Smooth Muscle Cell Migration via Phospho-Extracellular Signal-Regulated Kinase and Chloride Intracellular Channel 4. CIRCULATION RESEARCH, 105(7), 639-U37.
  
• Reactivation of gamma HV68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin Spiekerkoetter, E., Alvira, C. M., Kim, Y.-M., Bruneau, A., Pricola, K. L., & Rabinovitch, M. (2008). Reactivation of gamma HV68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 294(2), L276-L289.
  
• Experience with inhaled iloprost and bosentan in portopulmonary hypertension Hoeper, M. M., Seyfarth, H. J., Hoefflken, G., Wirtz, H., Spielkerkoetter, E., & Halank, M. (2007). Experience with inhaled iloprost and bosentan in portopulmonary hypertension. EUROPEAN RESPIRATORY JOURNAL, 30(6), 1096-1102.
  
• Mts1/S100A4 stimulates human pulmonary artery smooth muscle cell migration through multiple signaling pathways Spiekerkoetter, E., Lawrie, A., Merklinger, S., Ambartsumian, N., Lukanidin, D., & Rabbiovitch, M. (2005). Mts1/S100A4 stimulates human pulmonary artery smooth muscle cell migration through multiple signaling pathways. CHEST, 128(6), 577S-577S.
  
• Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Hoeper, M. M., Markevych, I., Spiekerkoetter, E., Welte, T., & Niedermeyer, J. (2005). Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. EUROPEAN RESPIRATORY JOURNAL, 26(5), 858-863.
  
• Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension Merklinger, S. L., Wagner, R. A., Spiekerkoetter, E., Hinek, A., Knutsen, R. H., & Rabinovitch, M. (2005). Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension. CIRCULATION RESEARCH, 97(6), 596-604.
  
• Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease Lawrie, A., Spiekerkoetter, E., Martinez, E. C., Ambartsumian, N., Sheward, W. J., & Rabinovitch, M. (2005). Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. CIRCULATION RESEARCH, 97(3), 227-235.
  
• Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids Hoeper, M. M., Taha, N., Bekjarova, A., Gatzke, R., & Spiekerkoetter, E. (2003). Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. EUROPEAN RESPIRATORY JOURNAL, 22(2), 330-334.
  
• Effects of inhaled salbutamol in primary pulmonary hypertension Spiekerkoetter, E., Fabel, H., & Hoeper, M. M. (2002). Effects of inhaled salbutamol in primary pulmonary hypertension. EUROPEAN RESPIRATORY JOURNAL, 20(3), 524-528.
  
• Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension Hoeper, M. M., Spiekerkoetter, E., Westerkamp, V., Gatzke, R., & Fabel, H. (2002). Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension. EUROPEAN RESPIRATORY JOURNAL, 20(2), 339-343.
  
• [Long-term treatment of primary pulmonary hypertension with inhaled iloprost]. Hoeper, M. M., Schwarze, M., Ehlerding, S., Adler-Schuermeyer, A., Spiekerkoetter, E., & Fabel, H. (2001). [Long-term treatment of primary pulmonary hypertension with inhaled iloprost]. Pneumologie (Stuttgart, Germany), 55(1), 38-43.
  
• Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. Hoeper, M. M., Schwarze, M., Ehlerding, S., Adler-Schuermeyer, A., Spiekerkoetter, E., & Fabel, H. (2000). Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. NEW ENGLAND JOURNAL OF MEDICINE, 342(25), 1866-1870.
  
• Prevalence of malignancies after lung transplantation Spiekerkoetter, E., Krug, N., Hoeper, M., Wiebe, K., Hamm, M., & Fabel, H. (1998). Prevalence of malignancies after lung transplantation. TRANSPLANTATION PROCEEDINGS, 30(4), 1523-1524.